Across TCGA pan-cancer cohorts, IGLV6-57 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IGLV6-57 data layer compared with 20 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IGLV6-57 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IGLV6-57 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where IGLV6-57 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.938	0.786	.003	22	view →
HNSC	DFS	Tertile	All	0.832	0.315	.014	12	view →
CCRCC	DFS	Median	III,IV	0.723	0.424	.021	7	view →
LSCC	DFS	Median	III,IV	0.531	0.935	.012	6	view →
LUAD	OS	Quartile	III,IV	0.483	0.899	.021	6	view →
GBM	DFS	Median	All	0.804	0.559	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: IGLV6-57 tumor-vs-normal RNA expression · all IGLV6-57 data types